共 108 条
[15]
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
[J].
ARTHRITIS AND RHEUMATISM,
2006, 54 (09)
:2793-2806
[18]
COOPER N, 2002, BLOOD, V100